Edison Investment Research - Prima Biomed Limited (PRR) Outlook: LAG-3 comes to the fore

Report

Edison Investment Research

Outlook: LAG-3 comes to the fore

Prima BioMed has switched its focus from CVac to IMP321 since acquiring the French immunotherapy company Immutep for A$26m. A Phase II study in metastatic breast cancer with IMP321 is due to start in H215; the product has potential across many tumours, with other immunotherapies and chemotherapy. CVac still has potential in ovarian cancer and other epithelial tumours, and Prima is looking for a partner to develop it further. Prima's two other assets gained with Immutep are partnered with GSK and Novartis. Our valuation is A$199m vs A$101m before the acquisition.

14/04/2015 12 EN

Underlying

Prima Biomed Limited

See profile

AU000000PRR9 Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

Immutep - AIPAC fully recruited, results due Q120

Immutepâ€™s AIPAC Phase IIb study of its antigen-presenting cell activator eftilagimod alpha (efti) plus chemotherapy in breast cancer is fully recruited and expected to report top-line data in Q120. The initial tranche of 17 subjects in the first-line lung cancer arm of the TACTI-002 study of efti plus Keytruda (in collaboration with US Merck) has completed enrolment; the cohort will be expanded to 36 subjects if more than four responses are observed (we expect initial response rate data in Q419). Enrolment in second-line lung and head and neck cancer is ongoing. Positive results in AIPAC or ...

July 2, 2019 July 2, 2019 12 EN

Edison Investment Research

Immutep - AIPAC fully recruited, results due Q120

July 2, 2019 July 2, 2019 12 EN

Edison Investment Research

Immutep - Encouraging results for efti and IMP761

Immutep presented encouraging data from TACTI-mel Part B and from preclinical studies of its novel LAG-3 agonist at recent scientific conferences. The AIPAC Phase II study of its APC activator eftilagimod alpha (efti) plus chemo in breast cancer is expected to report top-line data in Q419 or Q120. The TACTI-002 study of efti plus Keytruda in lung and head and neck cancers in collaboration with US Merck has enrolled over 10 subjects and is expected to report first data mid-year. Other in-house and partnered programs are also likely to produce significant news this year. We lift our valuation to...

April 8, 2019 April 8, 2019 12 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Outlook: LAG-3 comes to the fore

Immutep - AIPAC fully recruited, results due Q120

Immutep - AIPAC fully recruited, results due Q120

Immutep - Encouraging results for efti and IMP761

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe